MiR-7 attenuated NSCLC progression via targeting several oncogenes, such as PAK1, EGFR, RAF1, IRS1, and IRS2 that resulted in inhibition of the EGFR/AKT axis [31–34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.